← All trials
NCT04515732
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2018
- Primary completion
- Apr 30, 2021
- Completion date
- Oct 31, 2021
- First posted
- Aug 17, 2020
- Last posted
- Aug 17, 2020
- Enrollment
- 115
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- CelgeneCollaborator
- University of CopenhagenSponsor investigator
- The Danish Rheumatism AssociationCollaborator
- The Danish Psoriasis AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.